Outlook Therapeutics (OTLK) Cash from Investing Activities (2015 - 2019)
Outlook Therapeutics (OTLK) posted quarterly Cash from Investing Activities of -$1.0 for Q3 2019, up 100.0% year-over-year from -$0.5 in Q3 2018, and up 100.0% quarter-over-quarter from -$150737.0 in Q2 2019.
Outlook Therapeutics (OTLK) Cash from Investing Activities (2015 - 2019) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Cash from Investing Activities for 5 consecutive years, with -$1.0 the latest figure, recorded in Q3 2019.
- In Q3 2019, Cash from Investing Activities rose 100.0% year-over-year to -$1.0; the TTM figure through Sep 2020 stood at -$200874.0 (up 54.07% YoY), while the FY2020 annual figure was -$900000.0, down 105.81% from the prior year.
- Cash from Investing Activities rose to -$1.0 in Q3 2019 per OTLK's latest filing, from -$150737.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $46949.0 in Q1 2016 and bottomed at -$3.5 million in Q2 2015.
- Historically, Cash from Investing Activities has averaged -$632910.3 across 5 years, with a median of -$202226.5 in 2018.
- Annual changes were most pronounced in 2018 — Cash from Investing Activities slumped 5165.95% — and 2019, when it jumped 100.0%.
- Outlook Therapeutics' Cash from Investing Activities stood at -$364242.0 in 2015, then soared by 59.27% to -$148362.0 in 2016, then plunged by 624.68% to -$1.1 million in 2017, then jumped by 78.01% to -$236433.0 in 2018, then jumped by 100.0% to -$1.0 in 2019.
- Business Quant data shows OTLK's Cash from Investing Activities at -$1.0 in Q3 2019, -$150737.0 in Q2 2019, and -$50136.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -1.00 |
| Sep 30, 2019 | -1.00 |
| Jun 30, 2019 | -150,737.00 |
| Jun 30, 2019 | -150,737.00 |
| Mar 31, 2019 | -50,136.00 |
| Mar 31, 2019 | -50,136.00 |
| Dec 31, 2018 | -236,433.00 |
| Dec 31, 2018 | -236,433.00 |
| Sep 30, 2018 | -1.26 Mn |
| Sep 30, 2018 | -1.26 Mn |
| Jun 30, 2018 | -168,020.00 |
| Jun 30, 2018 | -168,020.00 |
| Mar 31, 2018 | -275,186.00 |
| Mar 31, 2018 | -275,186.00 |
| Dec 31, 2017 | -1.08 Mn |
| Dec 31, 2017 | -1.08 Mn |
| Sep 30, 2017 | -23,980.00 |
| Sep 30, 2017 | -23,980.00 |
| Jun 30, 2017 | -76,229.00 |
| Jun 30, 2017 | -76,229.00 |